A Phase 1 interventional study of Mirvetuximab soravtansine in Tumors, sponsored by ImmunoGen, Inc.. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-17.
Sponsored by ImmunoGen, Inc. (part of AbbVie) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to test mirvetuximab soravtansine (IMGN853) in participants with ovarian cancer and other FOLR-1 positive tumors.
The study consists of a dose-escalation phase that will evaluate 2 dosing schedules (Schedule A and Schedule B) of mirvetuximab soravtansine and up to 5 dose-expansion groups at the maximum tolerated dose (MTD). The first 4 escalation cohorts will be single participant cohorts. Subsequent escalation cohorts will use a standard 3+3 design, with each cohort consisting of 3 or 4 to 6 participants. Data were collected and analysed for the escalation and expansion groups by dose schedule and not by individual dose.
10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's enrollment of 206 is above the median of 60 across 7,712 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →ImmunoGen, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
First submitted before ImmunoGen, Inc. became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Time from prior therapy:
Exclusion Criteria
Serious concurrent illness, including, but not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive mirvetuximab soravtansine intravenous (IV) infusion on Day 1 of every 21-day (every 3 weeks \[Q3W\]) cycle. Dose escalation for this group schedule will start at 0.15 milligrams per kilogram (mg/kg) and proceed through 7.0 mg/kg. Doses calculated initially based on participant's total body weight (TBW); then from protocol amendment 5 onwards, calculated based on adjusted ideal body weight (AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
Drug: Mirvetuximab soravtansine
Participants will receive mirvetuximab soravtansine IV infusion on Days 1, 8, and 15 of every 28-day cycle. Dose escalation for this group schedule will start at 1.1 mg/kg (calculated based on AIBW) and proceed through 2.5 mg/kg. Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
Drug: Mirvetuximab soravtansine
Participants with epithelial ovarian cancer (EOC) will receive mirvetuximab soravtansine 6.0 mg/kg (maximum tolerated dose \[MTD\]) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminated the study.
Drug: Mirvetuximab soravtansine
Participants with endometrial cancer (EC) will receive mirvetuximab soravtansine 6.0 mg/kg (MTD) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
Drug: Mirvetuximab soravtansine
Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
Also known as: IMGN853
Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine
MTD was defined as the highest dose at which 1 or fewer among 6 participants or less than or equal to (\<=) 33 percent (%) experienced a dose-limiting toxicity (DLT) (calculated based on adjusted ideal body weight \[AIBW\]). AIBW was calculated as ideal body weight (IBW) + 0.4 \* (actual weight - IBW), where IBW for men was 0.9 \* height in centimeters (cm) - 88 and IBW for women was 0.9 \* height in cm - 92. DLT was defined as a treatment-emergent adverse event (TEAE) or abnormal laboratory value related to study treatment (that is, assessed as unrelated to disease, intercurrent illness, or concomitant medications), including those TEAEs and abnormal laboratory values that resulted in a failure to meet the criteria for re-treatment.
Time frame: Cycle 1 (21 days)
Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of Mirvetuximab Soravtansine
RP2D was determined by MTD. MTD was defined as the highest dose at which 1 or fewer among 6 participants or \<=33% experienced a DLT. DLT was defined as a TEAE or abnormal laboratory value related to study treatment (that is, assessed as unrelated to disease, intercurrent illness, or concomitant medications), including those TEAEs and abnormal laboratory values that resulted in a failure to meet the criteria for re-treatment. Available clinical data indicated that the MTD defined for the Q3W schedule was equal to the RP2D.
Time frame: Cycle 1 (21 days)
Number of Participants With TEAEs
An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 on following scale: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Serious AEs include death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as any AE that emerged on or after the first dose, and within 28 days of the last dose.
Time frame: From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Number of Participants With Shift From Baseline Grade <=2 in Clinical Laboratory Parameters to Grade 3 or Grade 4 on Study
Laboratory parameters included serum chemistry (alanine aminotransferase \[ALT\]/serum glutamic pyruvic transaminase \[SGPT\], aspartate aminotransferase \[AST\]/serum glutamic oxaloacetic transaminase \[SGOT\], albumin, alkaline phosphatase, bilirubin, calcium, creatinine, glucose, magnesium, phosphorous, potassium, sodium), hematology (hemoglobin, lymphocytes, neutrophils, platelets, white blood cells) and coagulation (international normalized ratio \[INR\], partial thromboplastin time \[PTT\]). Clinically significant laboratory values were defined as per NCI CTCAE v.03 Grade 3 or higher. A grading (severity) scale was provided with grades ranging from 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening or disabling), to 5 (death). Only participants who shifted from a baseline value of Grade \<=2 to a post-baseline Grade 3/4 on-treatment, are reported.
Time frame: From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings and Vital Signs
Physical examination included assessments of general appearance, skin, head (eyes, ears, nose, and throat), neck, lungs, heart, abdomen, back, lymph nodes, extremities, and neurological system. Vital signs included assessment of blood pressure, pulse rate, respiratory rate and body temperature.
Time frame: From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
Standard ECGs were performed in triplicate at 2- to 5-minute intervals during the study. A single ECG was performed at the end of treatment visit and as clinically indicated.
Time frame: Baseline up to end of treatment (EOT) (up to maximum 124 weeks)
Number of Participants With Treatment-Emergent Ocular AEs
Ocular AEs included keratopathy and blurred vision. An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs were defined as any AE that emerged on or after the first dose, and within 28 days of the last dose.
Time frame: From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Maximum Observed Plasma Concentration (Cmax) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D
Pharmacokinetic (PK) parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 minutes [min] of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Cmax of Free DM4 and S-Methyl DM4 at RP2D
PK parameters were calculated using standard non-compartmental methods. PK analysis of free N2'-\[4-\[(3-carboxypropyl)dithio\]-4-methyl-1-oxo-2-sulfopentyl\]-N2'-deacetylmaytansine (DM4) and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
AUC0-inf of Free DM4 and S-Methyl DM4 at RP2D
PK parameters were calculated using standard non-compartmental methods. PK analysis of free DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Area Under the Plasma Concentration-Versus Time Curve From Time of Dose Until Tlast (AUClast) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
AUClast of Free DM4 and S-Methyl DM4 at RP2D
PK parameters were calculated using standard non-compartmental methods. PK analysis of free DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Terminal Half-Life (t1/2) of Mirvetuximab Soravtansine,Total M9346A Antibody, DM4, and S-Methyl DM4 at RP2D
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, total M9346A antibody, DM4, and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Clearance (CL) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
CL of DM4 and S-Methyl DM4 at RP2D
PK parameters were calculated using standard non-compartmental methods. PK analysis of DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Time to Reach Maximum Observed Concentration (Tmax) of Mirvetuximab Soravtansine, Free DM4, S-Methyl DM4, and Total M9346A Antibody at RP2D
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, free DM4, S-methyl DM4, and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Volume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine Free DM4, S-Methyl DM4, and Total M9346A Antibody at RP2D
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, free DM4, S-methyl DM4, and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.
Time frame: From first dose of study drug until first BOR of CR or PR (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Duration of Response (DOR) as Assessed by RECIST v1.1
DOR was defined as the time from the date of the first response (CR or PR), whichever was recorded first, until the date of progressive disease (PD). PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was only defined for participants who had a BOR of CR or PR using the method of Kaplan-Meier.
Time frame: From the date of first response (CR or PR) until the date of PD (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Progression-Free Survival (PFS) as Assessed by RECIST v1.1
PFS was defined as the time from initiation of study drug until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
Time frame: From first dose of study drug until PD or death whichever occurred first (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Time to Progression (TTP) as Assessed by RECIST v1.1
TTP was defined as the time from initiation of study drug until PD, estimated using the method of Kaplan-Meier. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
Time frame: From first dose of study drug until PD (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Number of Participants With Anti-Drug Antibodies (ADA)
During the conduct of the study, a single immunogenicity assay was developed to concurrently detect human antibodies against all components of mirvetuximab soravtansine, including the humanized anti-FOLR1 antibody, the cleavable disulfide linker, and the cytotoxic maytansinoid, DM4. Therefore, immunogenicity results were reported as ADA titers, and did not distinguish between human anti-drug or anti-human titers.
Time frame: Baseline up to follow-up visit (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Number of Participants With Gynecologic Cancer Intergroup (GCIG) CA-125 Criteria Clinical Responses
CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The date of response corresponded to the date when the CA 125 level was first reduced by 50%.
Time frame: From first dose of study drug until CA-125 response (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
A total of 206 participants were enrolled in this study, of whom 69 participants (44 to receive Schedule A and 25 to receive Schedule B treatment) were entered in dose-escalation phase and 137 participants (113 with epithelial ovarian cancer \[EOC\] and 24 with endometrial cancer \[EC\]) were entered in dose-expansion phase. Doses calculated initially based on participant's total body weight (TBW); then from protocol amendment 5 onwards, calculated based on adjusted ideal body weight (AIBW).
| Milestone | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 1 | 9 | 18 | 7 | 5 | 5 | 4 | 9 | 7 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 2 | 1 | 1 | 1 | 9 | 18 | 7 | 5 | 5 | 4 | 9 | 7 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 1 | 1 | 1 | 9 | 18 | 7 | 5 | 5 | 4 | 9 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 1 | 1 | 1 | 8 | 13 | 5 | 4 | 3 | 3 | 6 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical progression | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Began new anticancer therapy | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 46 | 24 | 27 | 40 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 46 | 24 | 27 | 40 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 2 | 2 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 13 | 20 | 27 |
| Withdrew: Clinical progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 2 |
| Withdrew: Began new anticancer therapy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 2 | 5 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 0 | 3 |
| Withdrew: Other than specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
MTD was defined as the highest dose at which 1 or fewer among 6 participants or less than or equal to (\<=) 33 percent (%) experienced a dose-limiting toxicity (DLT) (calculated based on adjusted ideal body weight \[AIBW\]). AIBW was calculated as ideal body weight (IBW) + 0.4 \* (actual weight - IBW), where IBW for men was 0.9 \* height in centimeters (cm) - 88 and IBW for women was 0.9 \* height in cm - 92. DLT was defined as a treatment-emergent adverse event (TEAE) or abnormal laboratory value related to study treatment (that is, assessed as unrelated to disease, intercurrent illness, or concomitant medications), including those TEAEs and abnormal laboratory values that resulted in a failure to meet the criteria for re-treatment.
| mg/kg | Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly) |
|---|---|---|
| Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine | 6.0 | 2.0 |
RP2D was determined by MTD. MTD was defined as the highest dose at which 1 or fewer among 6 participants or \<=33% experienced a DLT. DLT was defined as a TEAE or abnormal laboratory value related to study treatment (that is, assessed as unrelated to disease, intercurrent illness, or concomitant medications), including those TEAEs and abnormal laboratory values that resulted in a failure to meet the criteria for re-treatment. Available clinical data indicated that the MTD defined for the Q3W schedule was equal to the RP2D.
| mg/kg | Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W) |
|---|---|
| Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of Mirvetuximab Soravtansine | 6.0 |
An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 on following scale: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Serious AEs include death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as any AE that emerged on or after the first dose, and within 28 days of the last dose.
| Participants | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 2 | 1 | 0 | 1 | 9 | 18 | 7 | 5 | 5 | 4 | 9 | 7 | 46 | 24 | 27 | 40 |
| SAEs | 2 | 1 | 0 | 0 | 0 | 5 | 1 | 2 | 2 | 3 | 4 | 4 | 18 | 11 | 9 | 17 |
| Grade >=3 TEAEs | 2 | 1 | 0 | 1 | 1 | 8 | 1 | 3 | 2 | 3 | 4 | 4 | 24 | 12 | 14 | 24 |
Laboratory parameters included serum chemistry (alanine aminotransferase \[ALT\]/serum glutamic pyruvic transaminase \[SGPT\], aspartate aminotransferase \[AST\]/serum glutamic oxaloacetic transaminase \[SGOT\], albumin, alkaline phosphatase, bilirubin, calcium, creatinine, glucose, magnesium, phosphorous, potassium, sodium), hematology (hemoglobin, lymphocytes, neutrophils, platelets, white blood cells) and coagulation (international normalized ratio \[INR\], partial thromboplastin time \[PTT\]). Clinically significant laboratory values were defined as per NCI CTCAE v.03 Grade 3 or higher. A grading (severity) scale was provided with grades ranging from 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening or disabling), to 5 (death). Only participants who shifted from a baseline value of Grade \<=2 to a post-baseline Grade 3/4 on-treatment, are reported.
| Participants | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose: Grade 0 to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Magnesium: Grade 2 to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| PTT: Grade 2 to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes: Grade 0 to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Lymphocytes: Grade 2 to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
Physical examination included assessments of general appearance, skin, head (eyes, ears, nose, and throat), neck, lungs, heart, abdomen, back, lymph nodes, extremities, and neurological system. Vital signs included assessment of blood pressure, pulse rate, respiratory rate and body temperature.
| Participants | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings and Vital Signs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Standard ECGs were performed in triplicate at 2- to 5-minute intervals during the study. A single ECG was performed at the end of treatment visit and as clinically indicated.
| Participants | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 1 | 1 | 0 |
Ocular AEs included keratopathy and blurred vision. An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs were defined as any AE that emerged on or after the first dose, and within 28 days of the last dose.
| Participants | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Ocular AEs | 0 | 0 | 0 | 0 | 1 | 4 | 2 | 5 | 0 | 3 | 0 | 2 | 24 | 9 | 14 | 18 |
Pharmacokinetic (PK) parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
| micrograms per milliliter (mcg/mL) | Mirvetuximab Soravtansine 6.0 mg/kg AIBW |
|---|---|
| Mirvetuximab soravtansine at Cycle 1 | 146.9 ± 30.14 |
| Mirvetuximab soravtansine at Cycle 3 | 154.6 ± 33.08 |
| Total M9346A antibody at Cycle 1 | 149.2 ± 33.74 |
| Total M9346A antibody at Cycle 3 | 170.4 ± 40.55 |
PK parameters were calculated using standard non-compartmental methods. PK analysis of free N2'-\[4-\[(3-carboxypropyl)dithio\]-4-methyl-1-oxo-2-sulfopentyl\]-N2'-deacetylmaytansine (DM4) and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
| nanograms per milliliter (ng/mL) | Mirvetuximab Soravtansine 6.0 mg/kg AIBW |
|---|---|
| DM4 at Cycle 1 | 5.014 ± 3.119 |
| DM4 at Cycle 3 | 5.016 ± 2.389 |
| S-methyl DM4 at Cycle 1 | 12.43 ± 12.39 |
| S-methyl DM4 at Cycle 3 | 9.974 ± 5.485 |
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
| hours*milligrams/milliliter (hr*mg/mL) | Mirvetuximab Soravtansine 6.0 mg/kg AIBW |
|---|---|
| Mirvetuximab soravtansine at Cycle 1 | 17.39 ± 4.341 |
| Mirvetuximab soravtansine at Cycle 3 | 20.40 ± 5.144 |
| Total M9346A antibody at Cycle 1 | 24.00 ± 7.316 |
| Total M9346A antibody at Cycle 3 | 37.27 ± 12.54 |
PK parameters were calculated using standard non-compartmental methods. PK analysis of free DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
| hours*nanograms/milliliter (hr*ng/mL) | Mirvetuximab Soravtansine 6.0 mg/kg AIBW |
|---|---|
| DM4 at Cycle 1 | 292.9 ± 129.2 |
| DM4 at Cycle 3 | 290.6 ± 98.52 |
| S-methyl DM4 at Cycle 1 | 2656 ± 2722 |
| S-methyl DM4 at Cycle 3 | 1928 ± 1108 |
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
| hr*mg/mL | Mirvetuximab Soravtansine 6.0 mg/kg AIBW |
|---|---|
| Mirvetuximab soravtansine at Cycle 1 | 16.44 ± 4.177 |
| Mirvetuximab soravtansine at Cycle 3 | 18.91 ± 4.940 |
| Total M9346A antibody at Cycle 1 | 20.27 ± 5.903 |
| Total M9346A antibody at Cycle 3 | 29.29 ± 9.613 |
PK parameters were calculated using standard non-compartmental methods. PK analysis of free DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
| hr*ng/mL | Mirvetuximab Soravtansine 6.0 mg/kg AIBW |
|---|---|
| DM4 at Cycle 1 | 246.0 ± 133.3 |
| DM4 at Cycle 3 | 270.1 ± 95.62 |
| S-methyl DM4 at Cycle 1 | 2485 ± 2536 |
| S-methyl DM4 at Cycle 3 | 1806 ± 1046 |
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, total M9346A antibody, DM4, and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
| hours | Mirvetuximab Soravtansine 6.0 mg/kg AIBW |
|---|---|
| Mirvetuximab soravtansine at Cycle 1 | 119.4 ± 22.58 |
| Mirvetuximab soravtansine at Cycle 3 | 127.8 ± 34.11 |
| Total M9346A antibody at Cycle 1 | 186.7 ± 54.04 |
| Total M9346A antibody at Cycle 3 | 218.8 ± 71.46 |
| DM4 at Cycle 1 | 73.80 ± 28.99 |
| DM4 at Cycle 3 | 80.62 ± 26.12 |
| S-methyl DM4 at Cycle 1 | 122.2 ± 25.23 |
| S-methyl DM4 at Cycle 3 | 130.4 ± 23.47 |
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
| milliliters per hour (mL/hr) | Mirvetuximab Soravtansine 6.0 mg/kg AIBW |
|---|---|
| Mirvetuximab soravtansine at Cycle 1 | 22.20 ± 6.476 |
| Mirvetuximab soravtansine at Cycle 3 | 19.80 ± 4.953 |
| Total M9346A antibody at Cycle 1 | 16.89 ± 7.155 |
| Total M9346A antibody at Cycle 3 | 13.26 ± 4.956 |
PK parameters were calculated using standard non-compartmental methods. PK analysis of DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
| Liters per hour (L/hr) | Mirvetuximab Soravtansine 6.0 mg/kg AIBW |
|---|---|
| DM4 at Cycle 1 | 1421 ± 560.2 |
| DM4 at Cycle 3 | 1338 ± 438.8 |
| S-methyl DM4 at Cycle 1 | 218.9 ± 128.5 |
| S-methyl DM4 at Cycle 3 | 258.4 ± 173.8 |
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, free DM4, S-methyl DM4, and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
| hours | Mirvetuximab Soravtansine 6.0 mg/kg AIBW |
|---|---|
| Mirvetuximab soravtansine at Cycle 1 | 3.80 (1.2 to 24) |
| Mirvetuximab soravtansine at Cycle 3 | 3.20 (1.1 to 47) |
| Total M9346A antibody at Cycle 1 | 3.60 (1.1 to 53) |
| Total M9346A antibody at Cycle 3 | 3.20 (0.93 to 170) |
| DM4 at Cycle 1 | 5.80 (1.7 to 500) |
| DM4 at Cycle 3 | 5.00 (1.1 to 670) |
| S-methyl DM4 at Cycle 1 | 49.0 (5.8 to 500) |
| S-methyl DM4 at Cycle 3 | 23.0 (4.5 to 670) |
PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, free DM4, S-methyl DM4, and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.
| Liters | Mirvetuximab Soravtansine 6.0 mg/kg AIBW |
|---|---|
| Mirvetuximab soravtansine at Cycle 1 | 3.198 ± 0.7422 |
| Mirvetuximab soravtansine at Cycle 3 | 3.172 ± 1.022 |
| Total M9346A antibody at Cycle 1 | 3.744 ± 0.9183 |
| Total M9346A antibody at Cycle 3 | 3.671 ± 1.185 |
| DM4 at Cycle 1 | 107400 ± 38770 |
| DM4 at Cycle 3 | 114300 ± 48740 |
| S-methyl DM4 at Cycle 1 | 41590 ± 27890 |
| S-methyl DM4 at Cycle 3 | 47520 ± 40440 |
ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.
| percentage of participants | Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly) | Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W) | Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|
| Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | 5 (0.6 to 15.8) | 13 (2.7 to 32.4) | 30 (21.8 to 39.4) | 8 (1.0 to 27.0) |
DOR was defined as the time from the date of the first response (CR or PR), whichever was recorded first, until the date of progressive disease (PD). PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was only defined for participants who had a BOR of CR or PR using the method of Kaplan-Meier.
| weeks | Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly) | Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W) | Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|
| Duration of Response (DOR) as Assessed by RECIST v1.1 | 21.3 (18.4 to 24.1) | 60.2 (44.3 to 76.1) | 19.3 (18.0 to 34.0) | 28.6 (NA to NA) |
PFS was defined as the time from initiation of study drug until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
| months | Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly) | Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W) | Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|
| Progression-Free Survival (PFS) as Assessed by RECIST v1.1 | 2.6 (1.3 to 3.3) | 3.9 (1.8 to 11.1) | 4.3 (3.9 to 5.4) | 2.8 (1.2 to 4.2) |
TTP was defined as the time from initiation of study drug until PD, estimated using the method of Kaplan-Meier. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
| months | Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly) | Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W) | Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|
| Time to Progression (TTP) as Assessed by RECIST v1.1 | 2.7 (1.3 to 3.3) | 3.9 (1.8 to 11.1) | 4.4 (4.0 to 5.6) | 2.8 (1.2 to 6.9) |
During the conduct of the study, a single immunogenicity assay was developed to concurrently detect human antibodies against all components of mirvetuximab soravtansine, including the humanized anti-FOLR1 antibody, the cleavable disulfide linker, and the cytotoxic maytansinoid, DM4. Therefore, immunogenicity results were reported as ADA titers, and did not distinguish between human anti-drug or anti-human titers.
| Participants | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Anti-Drug Antibodies (ADA) | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 7 | 2 | 2 |
CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The date of response corresponded to the date when the CA 125 level was first reduced by 50%.
| Participants | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Gynecologic Cancer Intergroup (GCIG) CA-125 Criteria Clinical Responses | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 2 | 2 | 3 | 23 | 4 | 11 | 17 |
Collected over From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | 1/18 (5.6%) | 5/18 (27.8%) | 18/18 (100%) |
| Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | 0/4 (0%) | 3/4 (75%) | 4/4 (100%) |
| Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | 1/9 (11.1%) | 4/9 (44.4%) | 9/9 (100%) |
| Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | 0/7 (0%) | 4/7 (57.1%) | 7/7 (100%) |
| Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | 4/46 (8.7%) | 18/46 (39.1%) | 45/46 (97.8%) |
| Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | 4/24 (16.7%) | 11/24 (45.8%) | 24/24 (100%) |
| Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | 1/27 (3.7%) | 9/27 (33.3%) | 27/27 (100%) |
| Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) | 4/40 (10%) | 17/40 (42.5%) | 40/40 (100%) |
| Event | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 0/2 | 0/1 | 1/1 | 0/1 | 0/9 | 1/18 | 0/7 | 0/5 | 0/5 | 1/4 | 1/9 | 0/7 | 2/46 | 0/24 | 0/27 | 7/40 |
| PneumoniaInfections and infestations | 1/2 | 0/1 | 0/1 | 0/1 | 0/9 | 1/18 | 0/7 | 0/5 | 0/5 | 0/4 | 0/9 | 0/7 | 1/46 | 1/24 | 0/27 | 1/40 |
| Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/2 | 0/1 | 0/1 | 0/1 | 0/9 | 0/18 | 0/7 | 0/5 | 0/5 | 0/4 | 0/9 | 0/7 | 0/46 | 0/24 | 1/27 | 1/40 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/2 | 0/1 | 0/1 | 0/1 | 0/9 | 1/18 | 0/7 | 0/5 | 0/5 | 1/4 | 0/9 | 0/7 | 1/46 | 0/24 | 0/27 | 0/40 |
| InfluenzaInfections and infestations | 0/2 | 0/1 | 0/1 | 0/1 | 0/9 | 0/18 | 0/7 | 0/5 | 0/5 | 1/4 | 0/9 | 0/7 | 0/46 | 0/24 | 0/27 | 0/40 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/2 | 0/1 | 0/1 | 0/1 | 0/9 | 0/18 | 0/7 | 0/5 | 0/5 | 1/4 | 0/9 | 0/7 | 0/46 | 0/24 | 0/27 | 0/40 |
| Punctate keratitisEye disorders | 0/2 | 0/1 | 0/1 | 0/1 | 0/9 | 0/18 | 0/7 | 1/5 | 0/5 | 0/4 | 0/9 | 0/7 | 0/46 | 0/24 | 0/27 | 0/40 |
| Hip fractureInjury, poisoning and procedural complications | 0/2 | 0/1 | 0/1 | 0/1 | 0/9 | 0/18 | 0/7 | 1/5 | 0/5 | 0/4 | 0/9 | 0/7 | 0/46 | 1/24 | 0/27 | 0/40 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/2 | 0/1 | 0/1 | 0/1 | 0/9 | 0/18 | 0/7 | 0/5 | 1/5 | 0/4 | 0/9 | 0/7 | 1/46 | 1/24 | 0/27 | 0/40 |
| HaematuriaRenal and urinary disorders | 0/2 | 0/1 | 0/1 | 0/1 | 0/9 | 0/18 | 0/7 | 0/5 | 1/5 | 0/4 | 0/9 | 0/7 | 0/46 | 0/24 | 0/27 | 0/40 |
| Event | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/2 | 0/1 | 1/1 | 0/1 | 1/9 | 5/18 | 1/7 | 0/5 | 0/5 | 1/4 | 3/9 | 1/7 | 4/46 | 2/24 | 4/27 | 7/40 |
| Vision blurredEye disorders | 0/2 | 0/1 | 0/1 | 0/1 | 1/9 | 3/18 | 2/7 | 5/5 | 0/5 | 3/4 | 0/9 | 2/7 | 23/46 | 7/24 | 11/27 | 16/40 |
| HypokalaemiaMetabolism and nutrition disorders | 0/2 | 0/1 | 0/1 | 1/1 | 0/9 | 1/18 | 1/7 | 1/5 | 1/5 | 0/4 | 1/9 | 0/7 | 10/46 | 6/24 | 1/27 | 8/40 |
| HeadacheNervous system disorders | 0/2 | 0/1 | 0/1 | 0/1 | 2/9 | 4/18 | 0/7 | 2/5 | 3/5 | 1/4 | 5/9 | 6/7 | 9/46 | 6/24 | 6/27 | 12/40 |
| Abdominal distensionGastrointestinal disorders | 0/2 | 0/1 | 0/1 | 0/1 | 0/9 | 0/18 | 0/7 | 0/5 | 0/5 | 3/4 | 0/9 | 2/7 | 3/46 | 1/24 | 1/27 | 8/40 |
| NauseaGastrointestinal disorders | 0/2 | 0/1 | 0/1 | 0/1 | 4/9 | 4/18 | 1/7 | 2/5 | 3/5 | 2/4 | 6/9 | 3/7 | 19/46 | 10/24 | 9/27 | 19/40 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/2 | 0/1 | 0/1 | 0/1 | 0/9 | 0/18 | 0/7 | 3/5 | 2/5 | 0/4 | 2/9 | 1/7 | 3/46 | 1/24 | 3/27 | 3/40 |
| FatigueGeneral disorders | 1/2 | 0/1 | 0/1 | 0/1 | 2/9 | 4/18 | 4/7 | 3/5 | 1/5 | 1/4 | 4/9 | 3/7 | 19/46 | 12/24 | 12/27 | 23/40 |
| TinnitusEar and labyrinth disorders | 0/2 | 0/1 | 0/1 | 0/1 | 0/9 | 0/18 | 0/7 | 0/5 | 3/5 | 0/4 | 0/9 | 0/7 | 2/46 | 1/24 | 0/27 | 0/40 |
| DiarrhoeaGastrointestinal disorders | 1/2 | 0/1 | 0/1 | 0/1 | 3/9 | 7/18 | 2/7 | 2/5 | 2/5 | 1/4 | 5/9 | 3/7 | 24/46 | 8/24 | 10/27 | 23/40 |
Safety population included all participants who were enrolled and received at least 1 dose of study drug.
| Age, Categorical(Participants) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 1 | 0 | 1 | 6 | 11 | 4 | 3 | 2 | 2 | 5 | 5 | 25 | 10 | 17 | 30 | 122 |
| >=65 years | 2 | 0 | 1 | 0 | 3 | 7 | 3 | 2 | 3 | 2 | 4 | 2 | 21 | 14 | 10 | 10 | 84 |
| Sex: Female, Male(Participants) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 1 | 1 | 9 | 16 | 5 | 4 | 4 | 4 | 9 | 7 | 46 | 24 | 27 | 40 | 200 |
| Male | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Not Hispanic or Latino | 2 | 1 | 1 | 1 | 9 | 16 | 7 | 3 | 4 | 4 | 9 | 6 | 44 | 23 | 26 | 33 | 189 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 7 | 13 |
| Race (NIH/OMB)(Participants) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 3 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 5 |
| White | 2 | 1 | 1 | 1 | 7 | 18 | 6 | 5 | 5 | 4 | 9 | 5 | 41 | 23 | 25 | 34 | 187 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2012 to primary completion in Mar 2018, 68 months.
Results were first posted in Feb 2021, 2 years 10 months after primary completion.
Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 68 months is above that.
Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirvetuximab soravtansine